Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00373516
Status:
COMPLETED
Last Update Posted:
2006-09-08
First Post:
2006-09-06
Brief Title:
Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis
Sponsor:
QuatRx Pharmaceuticals Company
Organization:
QuatRx Pharmaceuticals Company
Study Overview
Official Title:
A Multi-Center Randomized Double-Blind Parallel-Group Vehicle-Controlled Study of the Safety and Efficacy of Two Dosing Regimens of QRX-101 Becocalcidiol Ointment in the Treatment of Plaque-Type Psoriasis
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment 75 mcgg QD and 75mcgg BID in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None